LRMR Larimar Therapeutics
- 7.590
- -0.040-0.52%
- 7.560
- -0.030-0.40%
Larimar Therapeutics News
Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.2% on Wednesday.Shares of Worthington Enterprises, Inc. (NYSE:WOR) fell sharply in today's pre-market trading after
AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Monday.Shares of AMC Networks Inc. (NASDAQ:AMCX) fell sharply in today's pre-market trading after the compa
Moderna MRNA Candidate Chosen for FDA Rare Disease Therapy Acceleration Program
Larimar Therapeutics Insiders Placed Bullish Bets Worth US$540.7k
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in Larimar Therapeutics, Inc.'s (NASDAQ:LRMR) instance, it's good news for
Health Care Stocks Climb On Drug News -- Health Care Roundup
Health-care company shares climbed amid positive news for drug makers. The Food and Drug Administration approved Moderna's vaccine to protect against respiratory syncytial virus, a common virus that
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results.SentinelOne reported quarterly losses of 23 cents per share, which
Larimar Therapeutics Shares Rise 15% Nomlabofusp Selected for FDA Program
By Chris Wack Larimar Therapeutics shares were up 15% at $8.17 after the company said the Food and Drug Administration has selected nomlabofusp to participate in the Support for Clinical Trials Advan
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Friday.Shares of Ambarella, Inc. (NASDAQ:AMBA) rose sharply during Friday's session following strong first-quarter earnings and u
Buy Rating Affirmed for Larimar Therapeutics as FDA Accelerates Nomlabofusp's Path in START Pilot Program
Buy Rating on Larimar Therapeutics: Navigating FDA Approval With Promising FA Treatment
Express News | Larimar Therapeutics Inc: Selected by FDA to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia
START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseasesNomlabofusp was selected based on potential for clinical benefit in
Hello Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 0.5% on Tuesday.Shares of Hello Group Inc. (NASDAQ:MOMO) fell sharply in today's pre-market trading following
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Citi Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Raises Target Price to $14
Citi analyst Samantha Semenkow maintains $Larimar Therapeutics(LRMR.US)$ with a buy rating, and adjusts the target price from $10 to $14.According to TipRanks data, the analyst has a success rate of 4
Larimar Therapeutics Is Maintained at Buy by Citigroup
Larimar Therapeutics Is Maintained at Buy by Citigroup
Express News | Citigroup Maintains Buy on Larimar Therapeutics, Raises Price Target to $14
Express News | Larimar Therapeutics Inc : Citigroup Raises Target Price to $14 From $10
Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug
On Monday, Larimar Therapeutics Inc (NASDAQ:LRMR) announced that the FDA removed the previous partial clinical hold on -nomlabofusp (CTI-1601) clinical program for Friedreich's Ataxia (FA). Nomlabofus
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of James Hardie Industries plc (NYSE:JHX) fell sharply during Tuesday's session after the company reported worse-than-expected quarterly financial results.James Hardie Industries posted adjuste
Analysis
Price Target
No Data
